Why most peptides are not FDA approved

Most peptides are not FDA approved. The reason is almost always economic, not scientific. A handful did make it through. Wegovy and Ozempic (the brand names for semaglutide). Zepbound and Mounjaro (tirzepatide). Saxenda (liraglutide). Egrifta (tesamorelin). Each one is approved for specific conditions. Hundreds of other peptides with published research are not FDA approved. Some with decades of study behind them. And likely never will be.

Here's why. If you're researching peptides, you'll hit this question eventually. Bringing a drug through FDA approval costs $500 million to $2 billion. It takes ten to fifteen years. A pharmaceutical company will only spend that much on a molecule it can patent. The patent gives the company about twenty years of exclusive sales to recoup the investment. Most peptides cannot be patented. They are naturally occurring in the body. Or they were first described in scientific literature decades ago. Anyone can synthesize them. No patent means no commercial sponsor. No commercial sponsor means no large clinical trial program. No trial program means no FDA approval.

The peptides that did reach FDA approval are patentable modifications of naturally occurring hormones. Wegovy is one example. Lipid attachments to the natural GLP-1 peptide make it last days in the body instead of minutes. The modified molecule is patentable. So a company could fund the trials. So the trials happened. So FDA approval followed. The modification is what made the commercial case work, not the underlying biology.

This is the single most important thing to understand before you read about any specific peptide. 'Not FDA approved' does not usually mean 'does not work.' It does not usually mean 'is not safe.' It usually means no company had a patent strong enough to pay for the trial. Many of these compounds are legally prescribed today through specialty pharmacies. The FDA Status Tracker shows the current regulatory state of every peptide PSI covers.